Women with HIV may experience earlier menopause, heavier periods, and more vaginal infections. Transgender women with HIV face challenges, such as concerns about treatment interactions with ...

Alexis Perkins thought her OB-GYN's office in Atlanta would be just the place to get a prescription for the type of drug that reduces a person's risk of contracting HIV. But during a recent visit, the ...

Gilead said Thursday that twice-a-year injections of a new antiviral drug, called lenacapavir, completely protected cisgender women from contracting HIV in a large Phase 3 trial. In the study, none of ...

The Purpose 1 trial with 5,000 participants took place at three sites in Uganda and 25 sites in South Africa to test the efficacy of lenacapavir and two other drugs. Lenacapavir (Len LA) is a fusion ...

A new study found that the HIV treatment lenacapavir (Sunlenca) was completely effective at preventing HIV infection in women. Lenacapavir is administered as a twice-a-year shot. The drugmaker, Gilead ...

(CNN) — Two shots a year of a drug currently used to treat HIV infections were dramatically effective at preventing infections in a study among young women and adolescent girls in Africa. The ...

Lenacapavir, a twice-yearly injectable HIV-1 capsid inhibitor, has shown 100% efficacy in preventing HIV in women at a high risk for infection, according to an interim analysis of the phase 3 PURPOSE ...